

CONTENTS

CONTRIBUTORS	ix
PREFACE	xv
PART I BIOMARKERS AND THEIR ROLE IN DRUG DEVELOPMENT	1
1 Biomarkers Are Not New	3
<i>Ian Dews</i>	
2 Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care	15
<i>Gregory J. Downing</i>	
3 Enabling Go/No Go Decisions	31
<i>J. Fred Pritchard and Mallé Jurima-Romet</i>	
PART II IDENTIFYING NEW BIOMARKERS: TECHNOLOGY APPROACHES	41
4 Imaging as a Localized Biomarker: Opportunities and Challenges	43
<i>Jonathan B. Moody, Philip S. Murphy, and Edward P. Ficaro</i>	
5 Protein Biomarker Discovery Using Mass Spectrometry–Based Proteomics	101
<i>Joanna M. Hunter and Daniel Chelsky</i>	
6 Quantitative Multiplexed Patterning of Immune-Related Biomarkers	121
<i>Dominic Eisinger, Ralph McDade, and Thomas Joos</i>	

7	Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity	135
	<i>Jason A. Sprowl and Amadeo M. Parissenti</i>	
8	Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Molecules	155
	<i>Douglas M. Molina, W. John W. Morrow, and Xiaowu Liang</i>	
PART III CHARACTERIZATION AND VALIDATION		177
9	Characterization and Validation Biomarkers in Drug Development: Regulatory Perspective	179
	<i>Federico Goodsaid</i>	
10	Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development	187
	<i>Jean W. Lee, Yuling Wu, and Jin Wang</i>	
11	Molecular Biomarkers from a Diagnostic Perspective	215
	<i>Klaus Lindpaintner</i>	
12	Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulation	231
	<i>Francis Kalush and Steven Gutman</i>	
13	Importance of Statistics in the Qualification and Application of Biomarkers	247
	<i>Mary Zacour</i>	
PART IV BIOMARKERS IN DISCOVERY AND PRECLINICAL SAFETY		287
14	Qualification of Safety Biomarkers for Application to Early Drug Development	289
	<i>William B. Mattes and Frank D. Sistare</i>	
15	Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitor	301
	<i>Alan P. Brown</i>	
16	Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequences	323
	<i>Claire Cornips and Huub Schellekens</i>	
17	New Markers of Kidney Injury	335
	<i>Sven A. Beushausen</i>	

PART V TRANSLATING FROM PRECLINICAL RESULTS TO CLINICAL AND BACK	359
18 Translational Medicine—A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers	361
<i>Giora Z. Feuerstein, Salvatore Alesci, Frank L. Walsh, J. Lynn Rutkowski, and Robert R. Ruffolo, Jr.</i>	
19 Clinical Validation and Biomarker Translation	375
<i>David Lin, Andreas Scherer, Raymond Ng, Robert Balshaw, Shawna Flynn, Paul Keown, Robert McMaster, and Bruce McManus</i>	
20 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis	399
<i>Christina Trollmo and Lars Klareskog</i>	
21 Pharmacokinetic and Pharmacodynamic Biomarker Correlations	413
<i>J.F. Marier and Keith Gallicano</i>	
22 Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints	433
<i>Calvert Loudon and Ruth A. Roberts</i>	
PART VI BIOMARKERS IN CLINICAL TRIALS	443
23 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: Case Study in Anticoagulant Development	445
<i>Kay A. Criswell</i>	
24 Integrating Molecular Testing Into Clinical Applications	463
<i>Anthony A. Killeen</i>	
25 Biomarkers for Lysosomal Storage Disorders	475
<i>Ari Zimran, Candida Fratazzi, and Deborah Elstein</i>	
26 Value Chain in the Development of Biomarkers for Disease Targets	485
<i>Charles W. Richard, III, Arthur O. Tzianabos, and Whaijen Soo</i>	
PART VII LESSONS LEARNED: PRACTICAL ASPECTS OF BIOMARKER IMPLEMENTATION	493
27 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork	495
<i>Lena King, Mallé Jurima-Romet, and Nita Ichhpurani</i>	

28 Integrating Academic Laboratories Into Pharmaceutical Development	515
<i>Peter A. Ward and Kent J. Johnson</i>	
29 Funding Biomarker Research and Development Through the Small Business Innovative Research Program	527
<i>James Varani</i>	
30 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices	541
<i>Bruce D. Car, Brian Gemzik, and William R. Foster</i>	
31 Anti-Unicorn Principle: Appropriate Biomarkers Don't Need to Be Rare or Hard to Find	551
<i>Michael R. Bleavins and Ramin Rahbari</i>	
32 Biomarker Patent Strategies: Opportunities and Risks	565
<i>Cynthia M. Bott and Eric J. Baude</i>	
PART VIII WHERE ARE WE HEADING AND WHAT DO WE REALLY NEED?	575
33 IT Supporting Biomarker-Enabled Drug Development	577
<i>Michael Hehenberger</i>	
34 Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine	593
<i>Craig P. Webb, John F. Thompson, and Bruce H. Littman</i>	
35 Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection	625
<i>Heather Walmsley, Michael Burgess, Jacquelyn Brinkman, Richard Hegele, Janet Wilson-McManus, and Bruce McManus</i>	
36 Pathodynamics: Improving Biomarker Selection by Getting More Information from Changes Over Time	643
<i>Donald C. Trost</i>	
37 Optimizing the Use of Biomarkers for Drug Development: A Clinician's Perspective	693
<i>Alberto Gimona</i>	
38 Nanotechnology-Based Biomarker Detection	709
<i>Joshua Reineke</i>	
INDEX	731